SCK CEN at EANM’25

Radioligand therapy offers superb potential in the fight against cancer. Thanks to our many years of expertise in the nuclear field, direct access to radioisotopes and in-depth knowledge of dosimetry, we help develop precision treatments that specifically target tumours while avoiding healthy tissue as much as possible.

At SCK CEN, we bring together multidisciplinary expertise and specialised infrastructure to support various aspects of pre-clinical research. From receptors and tumour models to ligand development, conjugation and radiolabelling, pharmacokinetics, small-scale dosimetry and therapeutic efficacy; our expertise can be deployed in specific domains, depending on the requirements at each stage of the development process.

In this way, we support partners at specific stages of the preclinical process and help drive innovative radiopharmaceuticals towards clinical application.

With our BR2 research reactor, SCK CEN has specialised infrastructure to produce medical radioisotopes. BR2 supplies radioisotopes for the diagnosis and treatment of millions of patients worldwide.

Thanks to our nuclear expertise and central location in Europe, we ensure the reliable production and efficient distribution of medical radioisotopes.

With our Centralized Radiochemical Facility (CRF), SCK CEN has specialised infrastructure for the radiochemical purification of medical radioisotopes. Using advanced separation techniques, we facilitate the further development and production of existing and new medical isotopes and strive to achieve a high level of chemical and radionuclide purity, in accordance with European Pharmacopoeia standards.